Table 1.
Demographic and clinical data
| Parameter | 6–7 years | 13–14 years | 20–44 years | p |
|---|---|---|---|---|
| N | 130 | 132 | 159 | |
| Sex (female/male) | (52/78) | (69/63) | (103/56) | |
| Age years Me (min–max) |
7 (6–7) |
13 (13–14) |
29 (20–44) |
|
| BMI Me (min–max) |
15 (10–21) |
19 (13–27) |
23 (16–35) |
0.0002** |
| Asthma atopic % (N) | 1.5 % (2) | 4.5 % (6) | 3.1 % (5) | 0.37* |
| Asthma nonatopic % (N) | 4.6 % (6) | 1.5 % 9 (2) | 0.0 % (0) | 0.15* |
| Allergic rhinitis intermittent % (N) | 6.9 % (9) | 7.6 % (10) | 10.1 % (16) | 0.58* |
| Allergic rhinitis persistent % (N) | 11.5 % (15) | 16.7 % (22) | 15.1 % (24) | 0.48* |
| Healthya % (N) | 66.9 % (87) | 68.9 % (91) | 66.0 % (105) | 0.86* |
| Sensitization % of examined (N) | 28.4 % (37) | 39.4 % (52) | 44.0 % (70) | 0.02* |
| Asymptomatic sensitizationb % of sensitized (N) | 35.1 % (13) | 36.5 % (19) | 42.0 % (29) | 0.73* |
| Total IgE (IU/mL) Me (min–max) |
22.9 (0.8–808.3) |
13.8 (1.5–679.1) |
9.9 (0.2–1824.1) |
0.0002** |
N number of examined patients, Me median, Min minimum, Max maximum, % percentage of patients, p p value
* Chi-square test; ** Kruskal–Wallis test
aWithout any allergic disease and symptoms
bAsymptomatic sensitization was defined as the presence of sIgE antibodies detectable in skin tests or serological tests in patients showing no clinical allergic symptoms to a specific allergen